<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811171</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-0001</org_study_id>
    <nct_id>NCT03811171</nct_id>
  </id_info>
  <brief_title>Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study</brief_title>
  <official_title>A Study of the SonoMotion Break Wave(TM) System for the Comminution of Urinary Tract Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SonoMotion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SonoMotion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess&#xD;
      the safety and effectiveness of breaking stones in the upper urinary tract using the&#xD;
      SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be&#xD;
      performed in a hospital surgical environment as an outpatient (without being admitted) or in&#xD;
      a non-surgical environment such as a clinic or office procedure room. The procedure will be&#xD;
      performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia&#xD;
      (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm&#xD;
      everywhere else.&#xD;
&#xD;
      Safety will be measured by the self-reported occurrences of adverse events, unplanned&#xD;
      emergency department or clinic visits, and the need for further intervention. Fragmentation&#xD;
      will be measured by self-reported stone passage and a comparison of computed tomography (CT)&#xD;
      images before and after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Outcome - Stone Fragmentation</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>Stone fragmentation as determined by stone passage or imaging confirmation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Outcome - Hematoma, urinary tract sepsis, or cardiac arrythmia</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>The documented occurrence of clinically significant or symptomatic hematoma (perirenal/intrarenal), urinary tract sepsis, or serious cardiac arrythmia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary effectiveness outcome - Stone Free Status</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>Radiographic evidence (CT imaging) of stone free status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary effectiveness outcome - Residual fragment size</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>Presence of only stone fragments small enough to pass (less than or equal to 4 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety outcome - Adverse events</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>documented occurrence of all adverse events and comparison of the incidence (rate of occurrence) to the adverse events associated with shock wave lithotripsy (SWL)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Calculi</condition>
  <condition>Urinary Calculi</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Break Wave extracorporeal lithotripsy</intervention_name>
    <description>The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals presenting with at least one kidney stone apparent on CT.&#xD;
&#xD;
          -  Stones must be within the upper urinary tract.&#xD;
&#xD;
          -  Stones are indicated for SWL treatment per the American Urology Association (AUA) 2016&#xD;
             guidelines.8&#xD;
&#xD;
          -  Stones must be measured under CT to be within the AUA 2016 SWL guidelines (i.e. ≤ 10&#xD;
             mm for lower pole stones and ≤ 20 mm for non-lower pole stones).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute untreated urinary tract infection or urosepsis.&#xD;
&#xD;
          -  Uncorrected bleeding disorders or coagulopathies.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Uncorrected obstruction distal to the stone.&#xD;
&#xD;
          -  Patients receiving anticoagulants and who are unable or not willing to cease the&#xD;
             medication for the Break Wave procedure.&#xD;
&#xD;
          -  Stones that are not echogenically visible or cannot be positioned within the Break&#xD;
             Wave therapy focus.&#xD;
&#xD;
          -  Individuals belonging to a vulnerable group (pregnant, mentally disabled, prisoner,&#xD;
             etc.).&#xD;
&#xD;
          -  Patients unwilling to comply with the follow-up protocol, including post-procedure CT.&#xD;
&#xD;
          -  Individuals under 18 years of age.&#xD;
&#xD;
          -  Anatomic presentations preventing adequate positioning or delivery of the Break Wave&#xD;
             pulse.&#xD;
&#xD;
          -  Calcified abdominal aortic aneurysms or calcified renal artery aneurysms.&#xD;
&#xD;
          -  Solitary kidney&#xD;
&#xD;
          -  Comorbidity risks which, in at the discretion of the physician, would make the patient&#xD;
             a poor candidate for the Break Wave procedure, such as anatomical anomalies that may&#xD;
             not be conducive to adequate stone fragment passage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oren Levy, PhD</last_name>
    <phone>4156722631</phone>
    <email>oren.levy@sonomotion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Sur</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barb Burke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital Stone Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Chew</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sonomotion.com</url>
    <description>Sponsor Website</description>
  </link>
  <reference>
    <citation>Maxwell AD, Cunitz BW, Kreider W, Sapozhnikov OA, Hsi RS, Harper JD, Bailey MR, Sorensen MD. Fragmentation of urinary calculi in vitro by burst wave lithotripsy. J Urol. 2015 Jan;193(1):338-44. doi: 10.1016/j.juro.2014.08.009. Epub 2014 Aug 9.</citation>
    <PMID>25111910</PMID>
  </reference>
  <reference>
    <citation>Maxwell AD, MacConaghy B, Bailey MR, Sapozhnikov OA. An investigation of elastic waves producing stone fracture in burst wave lithotripsy. J Acoust Soc Am. 2020 Mar;147(3):1607. doi: 10.1121/10.0000847.</citation>
    <PMID>32237849</PMID>
  </reference>
  <reference>
    <citation>Sapozhnikov OA, Maxwell AD, Bailey MR. Modeling of photoelastic imaging of mechanical stresses in transparent solids mimicking kidney stones. J Acoust Soc Am. 2020 Jun;147(6):3819. doi: 10.1121/10.0001386.</citation>
    <PMID>32611160</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stone</keyword>
  <keyword>Lithotripsy</keyword>
  <keyword>Calculi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

